Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase (2010)
- Authors:
- Autor USP: SILVA, CARLOS HENRIQUE TOMICH DE PAULA DA - FCFRP
- Unidade: FCFRP
- Subjects: FARMACOTERAPIA (ESTUDO); NEOPLASIAS
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2010
- Source:
- Título do periódico: Journal of Molecular Graphics and Modelling
- ISSN: 1093-3263
- Volume/Número/Paginação/Ano: v. 28, n. 6, p. 513-523, 2010
-
ABNT
SILVA, Carlos Henrique Tomich de Paula da et al. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase. Journal of Molecular Graphics and Modelling, v. 28, n. 6, p. 513-523, 2010Tradução . . Acesso em: 23 abr. 2024. -
APA
Silva, C. H. T. de P. da, Silva, V. B. da, Resende, J., Rodrigues, P. F., Bononi, F. C., Benevenuto, C. G., & Taft, C. A. (2010). Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase. Journal of Molecular Graphics and Modelling, 28( 6), 513-523. -
NLM
Silva CHT de P da, Silva VB da, Resende J, Rodrigues PF, Bononi FC, Benevenuto CG, Taft CA. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase. Journal of Molecular Graphics and Modelling. 2010 ; 28( 6): 513-523.[citado 2024 abr. 23 ] -
Vancouver
Silva CHT de P da, Silva VB da, Resende J, Rodrigues PF, Bononi FC, Benevenuto CG, Taft CA. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase. Journal of Molecular Graphics and Modelling. 2010 ; 28( 6): 513-523.[citado 2024 abr. 23 ] - Química computacional no planejamento de candidatos a quimioterápicos
- Planejamento racional de inibidores de enzimas-alvo aplicado a diferentes doenças: modelagem, síntese, bioquímica e QSAR
- RNA interference in drug discovery
- Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design
- Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms
- Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia
- Identification of novel chemical entities for Adenosine receptor type 2A using molecular modeling approaches
- General aspects of lead finding and optimization in drug discovery
- Molecular dynamics, density functional theory, pharmacophore modeling, molecular interaction fields and ADME/tox investigation of novel bioactive compounds interacting with CDK2 surfaces
- Pharmacophore-based drug design of novel potential tau ligands for Alzheimer's disease treatment
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas